Sophion and CreaCell Announce Successful Demonstration of the Performance of HEK-hKir2.1 Cells on QPatch HT
Sophion and CreaCell announced today that the two companies successfully demonstrated the performances of HEK-hKir2.1 cells on QPatch HT.
(PRWEB) July 12, 2012
Inward rectifier potassium channels of the Kir2 subfamily are important determinants of the electrical activity of cardiac cells, and mutations of the Kir2.1 channels are associated with familial atrial fibrillation, Andersen-Tawil syndrome and short-QT syndrome.
Because human Kir2.1 is a relevant target in preclinical cardiac safety testing of drug compounds, Sophion and CreaCell demonstrate the functionality of the CreaCell’s HEK-hKir2.1 recombinant cell line on Sophion’s automated patch-clamp system QPatch HT. Current amplitudes, IV curves, Ba2+ currents, and chloroethylclonidine dose-response curves were analysed.
“Several of our customers have asked us for a QPatch-optimized cell line expressing clinically relevant hKir2.1 ion channels,” said Dr. Morten Sunesen, VP of Customer Relations at Sophion. “We are pleased to announce the first result of this fruitful collaboration with CreaCell and our customers will benefit.”
“The synergy between our two companies is natural and allows us to satisfy client demands” said Dr. Pierre-Yves Perche, CEO at CreaCell. “At the same time, through this partnership with Sophion and its extensive network of customers, CreaCell confirms its intentions of developing its position in the worldwide market.”
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9685616.htm